Novartis to review $600m global media business

Novartis: calls global media review
Novartis: calls global media review

Novartis, the pharmaceutical giant, is gearing up to launch a review of its estimated $600m global media business.

WPP's MEC is the incumbent on the global business, including in the UK.

In 2008 Novartis consolidated its US media planning and buying into MEC after moving its business from sibling agency Mindshare in a global realignment.

The company, which has a consumer health business that markets over the counter medicines such as Tixylix and Savlon, spent £9m in the UK in the past 12 months, according to Nielsen.

Novartis, which is headquartered in Basel, Switzerland, has three other businesses called Pharmaceuticals, Vaccines and Diagnostics, and Sandoz Generics, a global supplier of generic medicines that are produced after a popular medicine's patent has expired.

0
SHARES
Comment

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus
Brand Republic Jobs
Thousands of jobs across advertising, creative, marketing and media

Just published

Feel you're missing out?

GET THE
BRANDREPUBLIC
BULLETINS
Sign up

The Wall Blog

From our partners

Barnados "life story"

Heineken "rubbish"

Reebok "theatre of dreams"